US pharmaceutical giant Moderna is under serious scrutiny in the United Kingdom after allegations emerged that the company ...

Wall Street analysts expect Moderna (MRNA) to post quarterly loss of $2.92 per share in its upcoming report, which indicates a year-over-year increase of 4.9%. Revenues are expected to be $126.98 ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval commitment ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

The United States is already falling behind China in countless technological advancements, thanks to several Biden-era policies.

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $28.00. The ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...